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Abstract
Background: There is good evidence for the effectiveness of opioid substitution therapy (OST) for injecting drug
users (IDUs) in middle and high-income countries but little evidence regarding the provision of OST by non-
government organisations (NGOs) in resource-poor settings. This paper reports on outcomes of an NGO-based OST
program providing sub-lingual buprenorphine to opiate dependent IDUs in two north-east Indian states (Manipur
and Nagaland), a region where conflict, under-development and injecting of heroin and Spasmoproxyvon (SP) are
ongoing problems. The objectives of the study were: 1) to calculate OST treatment retention, 2) to assess the
impact on HIV risk behaviours and quality of life, and 3) to identify client characteristics associated with cessation
of treatment due to relapse.
Methods: This study involves analysis of data that were routinely and prospectively collected from all clients
enrolled in an OST program in Manipur and Nagaland between May 2006 and December 2007 (n = 2569, 1853 in
Manipur and 716 in Nagaland) using standardised questionnaires, and is best classified as operational research. The
data were recorded at intake into the program, after three months, and at cessation. Outcome measures included
HIV risk behaviours and quality of life indicators. Predictors of relapse were modelled using binary logistic
regression.
Results: Of all clients enrolled in OST during the month of May 2006 (n = 713), 72.8% remained on treatment after
three months, and 63.3% after six months. Statistically significant (p = 0.05) improvements were observed in
relation to needle sharing, unsafe sex, incidents of detention, and a range of quality of life measures. Greater
spending on drugs at intake (OR 1.20), frequently missing doses (OR 8.82), and having heroin rather than SP as the
most problematic drug (OR 1.95) were factors that increased the likelihood of relapse, and longer duration in
treatment (OR 0.76) and regular family involvement in treatment (OR 0.20) reduced the likelihood of relapse.
Conclusion: The findings from this operational research indicate that the provision of OST by NGOs in the severely
constrained context of Manipur and Nagaland achieved outcomes that are internationally comparable, and
highlights strategies for strengthening similar programs in this and other resource-poor settings.
Background
Opioid substitution therapy (OST) is an evidence-based
intervention for opiate dependant persons that replaces
illicit drug use with medically prescribed, orally adminis-
tered opiates such as buprenorphine and methadone.
OST reduces HIV risk behaviours and harms associated
with injecting (such as abscesses, septicaemia and
endocarditis), overdose and participation in criminal
activity, thereby improving the quality of life and health
of injecting drug users (IDUs) [1-6]. It is endorsed by
UNAIDS, UNODC and WHO as part of a comprehen-
sive package of nine core interventions for IDU
programs that collectively maximise impact for HIV
prevention and treatment [7]. However, most of the
evidence for OST effectiveness has been generated in
middle and high-income countries where programs are
mostly located in dedicated healthcare settings; evidence
regarding the outcomes of OST programs in low-
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income countries where OST is often provided in grass-
roots settings such as drop-in-centres, is limited [3,8].
There are an estimated 106,000-223,000 IDUs in India,
of whom only 5% are currently receiving OST, which is
mostly delivered by community-based services [9,10].
There is a real need for evidence regarding outcomes of
OST provision in India in order to strengthen the case
for scaling up of services.
This paper reports on outcomes of an OST program
providing buprenorphine to opiate dependent IDUs,
delivered by non-government organisations (NGOs) in
the north-east Indian states of Manipur and Nagaland.
These states make up a region geographically isolated
from the rest of India, and characterised by multiple
sources of conflict including a longstanding civil insur-
gent struggle, poverty and unemployment. Approxi-
mately 2% of the population in Manipur and Nagaland
inject drugs, [11] most commonly heroin and Spasmo-
proxyvon (SP, a synthetic opioid analgesic that contains
dextropropoxyphene, dicyclomine hydrochloride and
paracetamol). As a consequence, Manipur and Nagaland
are the two states with the highest HIV prevalence in
the country [11]. Both the epidemic and the response to
it are more mature in Manipur, where sentinel surveil-
lance data indicates that during the late 1990s HIV pre-
valence among IDUs approached 80% [12]. By 2007,
HIV prevalence among IDUs was much reduced being
18% in Manipur and 1.9% in Nagaland [13]. The
response to HIV and injecting drug use in this geo-poli-
tically complex environment was punitive and coercive,
but harm reduction interventions such as needle and
syringe exchange programs and condom distribution
have been government policy since the mid 1990s [14].
Project ORCHID (Organised Response for Comprehen-
sive HIV Interventions in the Districts of Nagaland and
Manipur) is a Bill & Melinda Gates Foundation-funded
HIV prevention project that has been working in selected
districts of Manipur and Nagaland since 2004. It supports
local partner NGOs to deliver a range of harm reduction
interventions in rural and urban settings. In 2006, Project
ORCHID initiated a buprenorphine-based OST program
delivered by 11 local partner NGOs, initially with funding
from the United Kingdom government’s Department for
International Developing (DFID), and subsequently from
the National AIDS Control Organisation (NACO) and
Emmanuel Hospital Association (EHA). The OST pro-
gram is based in the community, operated out of drop-in
centres. Sub-lingual buprenorphine is provided for regis-
tered IDUs seven days per week, and is administered by
trained health care workers (mostly nurses) under the
supervision of medical doctors, following a standardised
protocol. The program was initially rapidly over-sub-
scribed and waiting lists were created. The program is
more fully described elsewhere [15].
During the DFID-funded period of the program (May
2006 - December 2007) more detailed information
regarding characteristics of the clients and outcomes of
the program were systematically collected as part of
routine program monitoring. Analysis of these data were
undertaken in order to address the following objectives:
1) to calculate OST treatment retention at 3, 6, 9 and
12 months, 2) to assess the impact of OST on HIV risk
behaviours and quality of life, and 3) to identify client




This study involves analysis of data collected routinely
during the implementation of an OST program, and is
best classified as operational research, which can be
defined as “The search for knowledge on interventions,
strategies, or tools that can enhance the quality, effec-
tiveness or coverage of programmes in which the
research is being done” (p.711) [16]. There is a strong
connection between program monitoring and evaluation
and operational research. Study designs such as rando-
mised controlled trials generate new knowledge about
the efficacy of interventions in a controlled environment
with strict inclusion and exclusion criteria, whereas
operational research assesses effectiveness in routine set-
tings that are far less controlled. The findings from
operational research have direct and practical implica-
tions for health care delivery [16].
Data collection
Data were prospectively collected from all clients
enrolled in the OST program in Manipur and Nagaland
between May 2006 and December 2007 (n = 2569, 1853
in Manipur and 716 in Nagaland) at intake, three
months after entry into the program, and at cessation of
treatment (regardless of the reason) using standardised
questionnaires developed by the program. The question-
naires were interviewer-administered by the NGO nurse
or outreach worker, and took approximately thirty min-
utes to complete. It was not always possible to conduct
a face-to-face interview with clients at cessation of treat-
ment, especially if cessation was due to relapse, so
where necessary and possible, relevant information was
drawn from the client file.
Outcome measures
The intake and three month follow-up questionnaires
captured self-reported information on socio-demo-
graphic characteristics, drug use, HIV risk behaviours,
and quality of life. At cessation of treatment additional
information was recorded regarding reason for cessation,
family involvement during treatment, and adherence to
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treatment. Reasons for ceasing OST were categorised as:
completed the program (meaning that the clients had
withdrawn from buprenorphine and had not returned to
their past pattern of drug use at the time of discharge);
relapsed or involuntarily discharged (hereafter referred
to as relapsed); and unknown reason for cessation.
Analysis
Data were entered by the Project ORCHID monitoring
and evaluation team using EpiInfo, and analysed using
SPSS version 18. The statistical tests used were Chi-
square, t-test, and McNemar’s test, and statistical signifi-
cance was calculated using two-tailed tests at the 95%
confidence level. Clients who had ceased OST with an
unknown reason (n = 281) were excluded from the ana-
lysis, except when calculating OST treatment retention
and describing the client characteristics. In order to
calculate OST treatment retention at 3, 6, 9 and
12 months, all clients commencing OST during May 2006
(n = 713) were tracked over the subsequent 12 months.
The impact of OST on HIV risk behaviours and qual-
ity of life was assessed by comparing changes between
baseline and three month follow-up measures. Results
were differentiated by the programmatic status of clients
at the end of the data collection period i.e. completed
the program, relapsed, or still on OST.
To determine factors associated with reason for cessa-
tion we identified all clients who had ceased treatment
with a known reason for cessation (n = 895) i.e. those
who had either completed the program or had relapsed.
A binary logistic regression model was used to predict
the likelihood of relapse at cessation of treatment rather
than completion of the program. Unadjusted odds ratios
with p-values less than 0.1 were considered eligible for
the multivariate model, and gender and age were also
included. The forced entry procedure was used to enter
variables in the model.
Results
Client characteristics
Table 1 presents socio-demographic data for all clients at
entry to OST disaggregated by state. In both Manipur and
Nagaland, clients were predominantly male and the major-
ity had at least a high school level of education. Almost
half reported being unemployed and the most common
source of referral to OST was friends/peers. A small pro-
portion of the OST clients in Nagaland (13.2%) were
female sex workers. Ages ranged from 16 to 61 years in
Manipur with a mean age of 30.9 years. In Nagaland ages
ranged from 18 to 55, with a mean age of 30.0 years.
There was variation in drug use between Manipur and
Nagaland; at intake most clients in Manipur reported
commonly using heroin (90.7%) whilst in Nagaland
approximately equal proportions reported using heroin
and SP (63.1% and 68.3% respectively). Clients from
Nagaland more commonly reported use of other drugs
including alcohol (50.9%), Relipen (20.4%; combination
drug containing similar ingredients to SP) and Nitrosun
(26.4%; nitrazepam). The majority of OST clients in
Manipur identified heroin as their most problematic
drug (87.6%), while in Nagaland the most problematic
drug was evenly split between heroin and SP (50.2% and
47.7% respectively).
OST treatment retention
Of all clients enrolled in OST during the month of May
2006 (n = 713), 72.8% remained on treatment after
three months, and 63.3% after six months (Table 2). At
the end of one year, 50.8% were still on OST. Approxi-
mately two-thirds (63.6%) had what can be defined as a
positive outcome after one year i.e. 12.8% had com-
pleted the program and 50.8% were retained on treat-
ment. Slightly more than one-quarter (27.5%) had
ceased treatment at the end of one year due to relapse,
and the remaining 9% had ceased treatment with an
unknown outcome.
Impact of OST on HIV risk behaviours and quality of life
Substantial improvements in self-reported HIV risk
behaviours were observed among clients retained on
OST between intake and 3 months (Table 3). There
were significant reductions in needle sharing and unsafe
sex. At intake one-quarter of clients reported sharing
needles in the past month compared to 2% or less after
three months on OST. There was a significant decrease
in the proportion of clients being jailed/detained. Reduc-
tions in HIV risk behaviours were observed amongst all
clients on treatment, even those clients who went on to
cease OST due to relapse.
There was a consistent and marked improvement
observed in the quality of life measures when intake is
compared with three months after enrolment (Table 4).
Of the clients successfully followed-up at 3 months, the
proportion reporting a good quality of life had risen by
approximately 40-50%. Other statistically significant
improvements in quality of life were also evident includ-
ing increased attendance at social events, reduced
frequency of family conflict, and a reduction in work-
related absenteeism amongst those with a job. The
improvements in quality of life were observed amongst
all clients on treatment, even those clients who went on
to cease OST due to relapse. Notably, no statistically
significant changes were observed with respect to the
proportion of clients who were employed.
Reasons for cessation of OST treatment
Of the 895 clients who ceased OST treatment during
the data collection period, 57% (n = 510) left OST
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because they had relapsed, and 43% (n = 385) left
because they had completed the program without a
return to their previous pattern of drug use at the time
of discharge.
Binary logistic regression modeling was performed to
assess the relative impact of a range of factors on the
reason for cessation (Table 5). The dependent variable
was reason for cessation i.e. relapse versus completion
of the program. The model contained gender and age as
well as duration in treatment, most problematic drug,
amount of money spent daily on drugs at intake, fre-
quently missing more than two doses a week, and regu-
lar family involvement in treatment. This model
explained between 43.9% (Cox and Snell R square) and
58.6% (Nagelkerke R square) of the variance in reason
for cessation.
Gender and age were not statistically significant pre-
dictors of reason for cessation. Five variables made a
statistically significant contribution to the model; dura-
tion in treatment, most problematic drug, money spent
daily on drugs at intake, frequently missing doses, and
regular family involvement in treatment. Greater spend-
ing on drugs at intake, frequently missing doses, and
having heroin rather than SP as the most problematic
drug were factors that increased the likelihood of cessa-
tion due to relapse, and longer duration in treatment
and regular family involvement in treatment reduced
the likelihood of cessation due to relapse.
Among the clients who ceased treatment, those who
reported heroin as their most problematic drug were
almost twice as likely to relapse compared to those
reporting SP. Clients who frequently missed more than
two doses a week were almost nine times more likely to
cease treatment due to relapse. Every additional month
spent in treatment reduced the risk of cessation due to
relapse by 24%. Clients whose families were not regu-
larly involved in their OST treatment were five times
more likely to cease treatment due to relapse.
Discussion
This study aims to contribute to the evidence-base for
the provision of OST by NGOs in northeast India, a
Table 1 OST client socio-demographic characteristics at intake (n = 2569)*
Demographic characteristic Manipur n (%) Nagaland n (%) Demographic characteristic Manipur n (%) Nagaland n (%)
Sex Education
Male 1775 (96.3) 598 (85.1) No education 103 (5.6) 49 (6.9)
Female 69 (3.7) 105 (14.9) Primary school 450 (24.3) 147 (20.6)
High school 444 (24.0) 243 (34.1)
Marital Status Undergraduate 548 (29.6) 146 (20.5)
Married 873 (47.1) 361 (50.5) Graduate and above 306 (16.5) 128 (18.0)
Single 876 (47.3) 320 (44.8)
Separated/divorced 67 (3.6) 23 (3.2) Occupation
Widowed 36 (1.9) 11 (1.5) Unemployed 874 (48.6) 323 (45.3)
Small business 335 (18.6) 72 (10.1)
Source of referral Government 118 (6.6) 131 (18.4)
Friend/peer 950 (51.6) 370 (51.7) Labourer 213 (11.8) 3 (0.4)
Outreach worker 280 (15.2) 148 (20.7) Sex worker 1 (0.1) 94 (13.2)
Peer educator 287 (15.6) 95 (13.3) Selling drugs 2 (0.1) 3 (0.4)
Family 207 (11.2) 71 (9.9) Other 256 (14.2) 87 (12.2)
Nurse 6 (0.3) 1 (0.1)
Other 111 (6.0) 30 (4.2)
* Percentages were calculated excluding missing cases
Table 2 OST treatment retention and outcomes over one year for a cohort of clients enrolled in May 2006 (n = 713)
Retained on OST Ceased – completed the program Ceased – relapsed Ceased – reason unknown
n (%) n (%) n (%) n (%)
3 months 519 (72.8) 18 (2.5) 138 (19.4) 38 (5.3)
6 months 451 (63.3) 42 (5.9) 166 (23.3) 54 (7.6)
9 months 405 (56.8) 60 (8.4) 186 (26.1) 62 (8.7)
12 months 362 (50.8) 91 (12.8) 196 (27.5) 64 (9.0)
Armstrong et al. Harm Reduction Journal 2010, 7:29
http://www.harmreductionjournal.com/content/7/1/29
Page 4 of 7
complex setting where injecting drug use and a conse-
quent HIV epidemic present substantial public health
challenges. Previous studies have highlighted the positive
impact of OST on reducing HIV risk behaviours, and
improving the quality of life and health of IDUs, and the
findings of this study also support the efficacy of OST as
an intervention for people with opioid drug dependence.
HIV risk behaviours and socio-economic outcomes
A range of behavioural, social and economic benefits
were evident as early as three months into treatment,
and many of these benefits extended beyond the OST
clients to their families and communities. An important
outcome of the OST program was a substantial reduc-
tion in reported HIV risk behaviours, primarily unsafe
injecting and unsafe sex. Participation in the program
arguably reduced the risk of HIV transmission not only
for those attending the program but also for their sexual
partners (often wives) and children. Other studies have
also found that OST is associated with rapid reductions
in HIV risk behaviours [3,5,6,17].
Less family conflict has multiple positive flow-on
effects, especially for children. Fewer episodes of deten-
tion or imprisonment reduces exposure to HIV risks,
and suggests that less crime is being committed, an
important social outcome. One potential benefit of OST
programs not evident in this study is an increase in
employment for the clients. This may be due to the fact
that meaningful employment opportunities for relatively
well-educated young people in north-east India are
extremely limited. Additionally, many (male) drug users
in north-east India are cared for by their natal families,
so are not forced to do menial work in order to obtain
the basic necessities of life.
Retention in treatment
Retention in OST treatment in Manipur and Nagaland
(63% after six months) is comparable with retention
outcomes reported by a WHO collaborative study that
included sites from low, middle and high-income coun-
tries (approximately 70% after six months overall - only
55% in Australia) [3]. Retention in treatment is clearly
important for the success of OST programs. As the
findings from this research and other studies indicate,
the longer people are retained in an OST program, the
greater the likelihood that they will complete the pro-
gram rather than relapse [17].
Other studies have reported buprenorphine dose as an
important determinant of retention in the treatment
program (higher doses being associated with better
retention) [1]. While information about the dose of
buprenorphine at the point of cessation was recorded
for some of the clients in this study, the extent of miss-
ing data for this variable precluded meaningful analysis.
Implications for policies and programs
Almost half of the clients who ceased OST did so hav-
ing completed the program without returning to their
previous pattern of opiate drug use at the time of dis-
charge, whilst the other half ceased OST due to relapse.
Factors that significantly increased the likelihood of
ceasing treatment due to relapse were higher spending
on drugs at intake, frequently missing buprenorphine
doses, and reporting heroin as their most problematic
Table 3 Changes in HIV risk behaviours when intake is compared with three months after enrolment (disaggregated
by status of client at the end of the data collection period)
Intake 3 months p-value*
Had shared a needle during past month (%)
Completed the program (n = 297) 23.5 0.7 <0.001
Relapsed (n = 155) 25.8 1.3 <0.001
Still on OST (n = 847) 27.6 2.1 <0.001
All clients (n = 1299) 26.5 1.8 <0.001
Had an unsafe sexual encounter during past month (%)
Completed the program (n = 260) 14.6 9.6 0.11
Relapsed (n = 138) 15.4 4.3 0.01
Still on OST (n = 818) 15.5 7.6 <0.001
All clients (n = 1216) 15.3 7.6 <0.001
Had been jailed/detained during past month (%)
Completed the program (n = 297) 10.8 0.3 <0.001
Relapsed (n = 155) 12.9 0.0 <0.001
Still on OST (n = 841) 11.7 1.1 <0.001
All clients (n = 1293) 11.6 0.8 <0.001
* McNemar’s Test
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drug. Longer duration in treatment and regular family
involvement significantly decreased the likelihood of
relapse.
Strategies to strengthen retention rates need to be
identified and implemented in order to achieve success-
ful outcomes for a larger proportion of clients. Facilitat-
ing family involvement in OST treatment could help to
achieve better outcomes for clients, as might active fol-
low-up and additional support for clients who are regu-
larly missing buprenorphine doses and for those who
identified heroin (rather than SP) as their most proble-
matic drug. Additionally, given that a large proportion
of clients who relapse leave the program in the first few
weeks, more intensive support for clients over the first
months of treatment may be beneficial.
Clients classified as “completing the program” were
not necessarily totally abstinent, but were no longer
requiring buprenorphine and had not returned to their
former pattern of drug use at the time of discharge.
Substantial reductions in drug use and HIV risk beha-
viours should be the goal of OST, rather than absti-
nence [17]. A systematic review of published research
from 1966 to 2003 reported that post-treatment absti-
nence rates varied between 22% and 86%; overall 33% of
former OST (methadone) patients were abstinent from
at least opioids for an average of more than two years
after completing detoxification [18]. Another review of
OST research conducted in Germany (methadone)
reported that only 10% of clients became totally absti-
nent, and identified the concern that attempts to intro-
duce time-limited (abstinence-oriented) treatment would
result in relapse and physical and psychological instabil-
ity [19]. It is probable that the situation is similar in
north-east India i.e. only a small proportion of OST cli-
ents are likely to achieve long-term total abstinence.
Many will need to remain in the program for years, and
some will require lifelong treatment.
Limitations
An important limitation of this analysis is that the data
were based primarily on self-report measures. Social
acceptability bias may have influenced the IDUs to
understate the extent to which they were engaging in
HIV risk behaviours, particularly given that the data
were being collected by program staff, though the com-
parability of the results with controlled trials suggests
that any effect of this kind may have been minimal. The
OST program in north-east India was better resourced
when funded by DFID than is currently the case (OST
is now funded by government), so we cannot assume
that current outcomes are the same as those reported in
this study.
The length of follow-up is too short to draw any firm
conclusions about longer-term outcomes for these OST
clients. A prospective longitudinal cohort study to sys-
tematically follow OST clients for 1-2 years would pro-
vide valuable information about outcomes for OST
clients, the impact of various dosing schedules, social
and economic benefits, program costs, and the extent to
which clients are cycling in and out of the program.
Additionally, it would be useful to follow clients who
cease treatment (for whatever reason) to compare the
benefits of staying in treatment over those of leaving. A
qualitative investigation to follow-up clients who relapse,
in order to better understand their reasons for relapse,
would contribute to more effective programming.
The findings from this study indicate that this OST
program in Manipur and Nagaland, which was imple-
mented by NGOs in a severely constrained context
Table 4 Changes in quality of life indicators when intake
is compared with three months after enrolment





Clients reporting a good quality of life
(%)
Completed the program (n = 297) 14.5 65.7 <0.001
Relapsed (n = 155) 17.4 54.8 <0.001
Still on OST (n = 849) 13.0 63.5 <0.001
All clients (n = 1301) 13.8 63.0 <0.001
Employed (%)
Completed the program (n = 297) 52.5 51.2 0.69
Relapsed (n = 155) 53.5 47.1 0.11
Still on OST (n = 844) 53.8 52.6 0.52
All clients (n = 1296) 53.5 51.6 0.17
Days in family conflict during past
month (mean)
Completed the program (n = 293) 4.6 0.5 <0.001+
Relapsed (n = 152) 4.1 0.8 <0.001+
Still on OST (n = 833) 4.6 0.7 <0.001+
All clients (n = 1278) 4.5 0.6 <0.001+
Social events attended during past
month (mean)
Completed the program (n = 297) 1.3 2.0 <0.001+
Relapsed (n = 155) 1.3 1.8 0.03+
Still on OST (n = 841) 1.3 2.0 <0.001+
All clients (n = 1293) 1.3 1.9 <0.001+
Day absent from work during past
month (mean)
Completed the program (n = 126) 2.5 0.6 <0.001+
Relapsed (n = 62) 1.9 1.0 0.22+
Still on OST (n = 350) 2.8 1.2 <0.001+
All clients (n = 538) 2.6 1.0 <0.001+
* McNemar’s Test performed unless otherwise stated
+ Paired t-test
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managed to achieve outcomes that are internationally
comparable. It has arguably made an important contri-
bution to HIV prevention in the region, as well as
improving the quality of life for a large group of people
with opioid dependence, their families and communities.
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Table 5 Binary logistic regression model to predict the likelihood of relapse from OST treatment (n = 895)
Variable Unadjusted Odds Ratio (95% C.I.) p-value Adjusted Odds Ratio (95% C.I.) p-value
Male 1.22 (0.74, 2.02) 0.44 0.82 (0.34, 2.01) 0.67
Age (years) 1.01 (0.99, 1.04) 0.20 1.01 (0.97, 1.05) 0.63
Duration in treatment (months) 0.74 (0.71, 0.77) <0.001 0.76 (0.72, 0.80) <0.001
Heroin as the most problematic drug (ref: SP) 1.31 (0.96, 1.78) 0.09 1.95 (1.16, 3.28) 0.01
Money spent daily on drugs at intake (Rs 100 units) 1.18 (1.05, 1.33) 0.01 1.20 (1.00, 1.44) 0.05
Frequently missed more than two doses a week 14.67 (9.21, 23.35) <0.001 8.82 (4.99, 15.63) <0.001
Regular family involvement in treatment 0.11 (0.08, 0.15) <0.001 0.20 (0.13, 0.30) <0.001
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